Bristol-Myers Squibb

Bristol-Myers Squibb, Ono Pharmaceutical collaborate in Japan, South Korea, Taiwan

Monday, July 28, 2014 02:54 PM

Bristol-Myers Squibb and Ono Pharmaceutical have signed a strategic collaboration agreement to jointly develop and commercialize multiple immunotherapies as single agents and combination regimens to help address the unmet medical needs of patients with cancer in Japan, South Korea and Taiwan.

More... »

WIRB Copernicus Group

ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

CRF Health eCOA webinar series

Covance adds two to clinical development services leadership team

Monday, July 14, 2014 01:04 PM

Covance has announced two key additions to its clinical development services scientific leadership team with the appointments of Robert Wasserman, M.D., as vice president and global therapeutic area head, oncology, and Rogelio Mosqueda-Garcia, M.D., Ph.D., as global vice president, early clinical services within medical and scientific affairs. Both are based in Princeton, N.J.

More... »

Bristol-Myers Squibb, Duke Clinical Research Institute collaborate

Wednesday, June 25, 2014 02:15 PM

Bristol-Myers Squibb is collaborating with Duke University through its Duke Clinical Research Institute (DCRI), focusing on clinical trial transparency. BMS will expand access to a broader set of clinical trial information from in-scope, company-sponsored studies and enable an independent scientific review through DCRI of requests from researchers that meet pre-specified requirements.

More... »

OptiNose adds three to operations, regulatory affairs and commercialization

Thursday, June 12, 2014 12:34 PM

OptiNose, a global specialty pharmaceuticals company, has announced three appointments to the company's senior management team.

More... »

Bristol-Myers Squibb, Syngene International extend research collaboration

Monday, June 9, 2014 01:56 PM

Bristol-Myers Squibb and Syngene International, a CRO based in India, have announced a five-year extension of their drug discovery and development collaboration in India. Financial terms have not been disclosed.

More... »

Bristol-Myers Squibb collaborates with CytomX Therapeutics, Incyte

Wednesday, May 28, 2014 01:01 PM

Bristol-Myers Squibb has formed two separate collaboration agreements. BMS and CytomX Therapeutics are collaborating on novel therapies against multiple immuno-oncology targets using CytomX’s proprietary Probody Platform. BMS and Incyte, a Wilmington, Del.-based biopharmaceutical company, have established a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of a combination regimen of BMS’ investigational PD-1 immune checkpoint inhibitor nivolumab and Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor INCB24360, in a phase I/II study.

More... »

Bristol-Myers Squibb, Celldex Therapeutics to collaborate

Thursday, May 15, 2014 01:24 PM

Bristol-Myers Squibb and Celldex Therapeutics have entered into a clinical trial collaboration to evaluate the safety, tolerability and preliminary efficacy of nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, and varlilumab, Celldex’s CD27 targeting investigational antibody in a phase I/II study.

More... »

Bristol-Myers Squibb acquires iPierian

Wednesday, April 30, 2014 11:39 AM

Bristol-Myers Squibb has acquired iPierian, a privately held biotechnology company focused on the discovery and development of new treatments for Tauopathies, a class of neurodegenerative diseases associated with the pathological aggregation of Tau protein in the human brain.

More... »

Trial results for AbbVie’s Hepatitis C candidate heat up race for effective treatment

Monday, April 14, 2014 12:51 PM

The race to replace interferon with a far more effective treatment for hepatitis C has become one of the most promising and lucrative battles in drug development, as AbbVie, Gilead Sciences, Merck and Bristol-Myers Squibb vie for the finish line.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 28

WCG acquires Alliance Biosciences to expand its biosafety oversight capabilities, ensure compliance

Facilitated review meetings for protocol design catching on, decreasing amendments, complexity

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs